Form 4: Soleno Therapeutics Senior VP Sells Shares Under Pre-Arranged Trading Plan

Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics, sold 3,830 shares of common stock for $82.76 per share on July 1, 2025, under a Rule 10b5-1 trading plan.

Summary

• Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (SLNO), reported a sale of common stock.
• The transaction involved the disposition of 3,830 shares of common stock.
• The sale occurred on July 1, 2025, at a price of $82.76 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Hirano on September 13, 2024.
• Following this transaction, Ms. Hirano beneficially owns 13,206 shares of Soleno Therapeutics common stock directly.
• A portion of the beneficially owned securities are Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Sentiment

Score: 5

Explanation: The transaction is an insider sale, which can be perceived negatively, but it was conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about it being based on new negative information. It's a routine disclosure for an insider transaction.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct ownership in the company.

Risks

• Potential investor perception of reduced insider confidence due to share sale, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Management Comments

• The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person September 13, 2024.
• Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight reduction in insider confidence, though the 10b5-1 plan mitigates this.

Key Dates

Recommendation

Keywords

Soleno Therapeutics, SLNO, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Patricia C. Hirano, Regulatory Affairs, Common Stock, RSU